TY - JOUR T1 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2021-002435 VL - 9 IS - 6 SP - e002435 AU - Julie R Brahmer AU - Hamzah Abu-Sbeih AU - Paolo Antonio Ascierto AU - Jill Brufsky AU - Laura C Cappelli AU - Frank B Cortazar AU - David E Gerber AU - Lamya Hamad AU - Eric Hansen AU - Douglas B Johnson AU - Mario E Lacouture AU - Gregory A Masters AU - Jarushka Naidoo AU - Michele Nanni AU - Miguel-Angel Perales AU - Igor Puzanov AU - Bianca D Santomasso AU - Satish P Shanbhag AU - Rajeev Sharma AU - Dimitra Skondra AU - Jeffrey A Sosman AU - Michelle Turner AU - Marc S Ernstoff Y1 - 2021/06/01 UR - http://jitc.bmj.com/content/9/6/e002435.abstract N2 - Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients. ER -